Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being
developed for treatment of hidradenitis suppurativa (HS).
This study will evaluate the efficacy, safety, and immunogenicity of izokibep administered
subcutaneously (SC) in adult subjects with moderate to severe HS.